| Name | Title | Contact Details |
|---|
At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals` quality of life and to shaping together the future of animal health.
You knew us as PHS Health Solutions, Touchpoint, Tardis Medical, and PDI, a family of leading pharmaceutical contract commercial organizations with a reputation as a trusted partner to our clients. And we`re still all that - but now we`re Amplity Health. Our vision is singular, so we wanted our corporate identity to match. We`ve consolidated our family of brands to offer customized and multichannel medical, remote engagement, and sales solutions, along with strategic consulting and organizational capability development into one company - and with one name—Amplity. Amplity is a new pure-play pharmaceutical commercialization partner that enjoys a 35-year track record. Our client-first passion elevates, accelerates, and amplifies commercial success from product to patient.
We make employer mental health benefits easily accessible. Request a demo today.
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare and orphan diseases.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia